DS

Daniel Spiegelman

Mr Spiegelman served as Executive Vice President, Chief Financial Officer of BioMarin Pharmaceutical Inc., a biotechnology company. From May 2009 to May 2012, Mr Spiegelman served as a consultant to provide strategic financial management support to a portfolio of public and private life science companies. Mr Spiegelman has also served as a member of the board of directors of Myriad Genetics, a molecular diagnostic company since May 2020, a Director of Jiya Acquisitions Corp since November 2020 and a Director of Spruce Bioscience since September 2020.

Holding

Company
Last Notice
Direct Shares
Indirect Shares
Options
Convertibles
28/09/23N/AN/A2,000,000N/A

Transactions

Company
Date
Type
Amount
Price
Value
Notes
01/03/21
Issued
2,000,000$1.580$3,160,000Issue of options